Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Access to advanced diagnostic imaging has taken a significant leap forward with the introduction of Gallium-68 Dotatate PET-CT scans onboard a mobile imaging unit.
Mobile Health Group and Mercy Radiology partnered together in 2024 to roll out Mobile Imaging, bringing specialist scans closer to patients across Aotearoa.
Dr Remy Lim, Medical Director of Mercy Radiology, says: “The introduction of Gallium-68 Dotatate PET-CT scans on the mobile unit is a real milestone. By bringing advanced diagnostic services directly to local communities, Mobile Imaging helps reduce the burden on patients who would otherwise need to travel long distances for these scans.”
This service not only saves patients from long and costly journeys but also gives clinicians faster access to the imaging they need to plan NET cancer treatment.
Related resources
More like this →
SCAN 2025: New Zealand leads on access, but patients still wait
New Zealanders with NETs rarely pay for treatment and have world-leading access to PRRT – but 59% report delays, and only 37% have heard of clinical trials. The SCAN 2025 findings, in full.
Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Lanreotide now funded in New Zealand for neuroendocrine tumours
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.